Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 03 - 20 crawled time : 16:20 save search
BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society's Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide
Published: 2021-03-20 (Crawled : 16:20) - investors.biomarin.com
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
| Email alert
Add to watchlist
presentation treatment drop endocrine children achondroplasia
Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201’s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency
Published: 2021-03-20 (Crawled : 16:20) - globenewswire.com
LUMO | $2.57 -1.91% -1.95% 12K
|
Health Technology
| Email alert
Add to watchlist
potential growth hormone growth hormone
BridgeBio Pharma Announces Proof-of-Concept Data of Encaleret in ADH1 at the Endocrine Society’s 2021 Annual Meeting
Published: 2021-03-20 (Crawled : 16:20) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
| Email alert
Add to watchlist
endocrine pharma
Theratechnologies Announces New Data Demonstrating Tesamorelin’s Positive Effect on Immune Response Linked to Liver Inflammation
Published: 2021-03-20 (Crawled : 16:20) - globenewswire.com
THTX | $1.29 -12.78% 8.1K
|
Health Technology
| Email alert
Add to watchlist
positive liver response
89bio Presents Additional Analysis of Phase 1b/2a NASH Study at the Annual ENDO 2021 Conference
Published: 2021-03-20 (Crawled : 16:20) - globenewswire.com
ETNB | $9.08 2.25% 2.2% 1M
|
Health Technology
| Email alert
Add to watchlist
phase 1 nash conference phase 1b phase 2b
Rhythm Pharmaceuticals Presents New Data from Phase 2 Basket Study Showing Continued Weight Loss at Up to Nine Months in Patients with HET Obesity on Setmelanotide at ENDO 2021
Published: 2021-03-20 (Crawled : 16:20) - globenewswire.com
RYTM A | $37.975 -0.35% -0.36% 620K
|
Health Technology
| Email alert
Add to watchlist
weight loss obesity phase 2 setmelanotide
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.